Renascience Inc. Logo

Renascience Inc.

Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.

4889 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
仙台市青葉区星陵町2−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Renascience Inc. is a research and development company engaged in the development and commercialization of pharmaceuticals and medical devices. The company focuses on creating innovative treatments derived from basic research to address various medical issues, including diseases associated with aging and hereditary conditions. Its R&D pipeline includes new drug candidates, such as antisense oligonucleotides, and advanced medical technology, such as a programmed medical device that utilizes artificial intelligence (AI) to support hemodialysis. Renascience actively forms strategic collaborations with pharmaceutical partners and academic institutions to advance its development projects and bring novel therapies to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-03 08:37
Regulatory News Service
確認書
Japanese 8.7 KB
2025-09-03 08:30
Regulatory News Service
訂正有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 1.7 MB
2025-06-27 08:35
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2025-06-24 08:36
Governance Information
内部統制報告書-第26期(2024/04/01-2025/03/31)
Japanese 23.2 KB
2025-06-24 08:35
Registration Form
確認書
Japanese 8.7 KB
2025-06-24 08:33
Registration Form
有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2024-11-14 07:37
Interim Report
確認書
Japanese 8.7 KB
2024-11-14 07:36
Interim Report
半期報告書-第26期(2024/04/01-2025/03/31)
Japanese 288.9 KB
2024-06-28 04:56
Post-Annual General Meeting Information
臨時報告書
Japanese 24.5 KB
2024-06-28 04:32
Governance Information
内部統制報告書-第25期(2023/04/01-2024/03/31)
Japanese 22.7 KB
2024-06-28 04:26
Registration Form
確認書
Japanese 8.7 KB
2024-06-28 04:24
Annual Report
有価証券報告書-第25期(2023/04/01-2024/03/31)
Japanese 3.5 MB
2024-05-27 10:10
Board/Management Information
臨時報告書
Japanese 22.4 KB
2024-02-08 07:46
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-08 07:45
Quarterly Report
四半期報告書-第25期第3四半期(2023/10/01-2023/12/31)
Japanese 235.8 KB

Automate Your Workflow. Get a real-time feed of all Renascience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Renascience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
NATURECELL CO.,LTD. Logo
Biotech company developing stem cell therapies, food, beverages, and cosmetics.
South Korea 007390
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893

Talk to a Data Expert

Have a question? We'll get back to you promptly.